^Ad hoc announcement pursuant to Art. 53 LR * Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO(TM) (aprocitentan) as the first and only endothelin receptor antagonist for the treatment of...

^Ad hoc announcement pursuant to Art. 53 LR * TRYVIO(TM) (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled...